

Hemoglobin A1c levels do not predict primary arteriovenous fistula failure in hemodialysis patients

Betül Nur Keser¹, Feyza Kaya², Verda Sandal³, Ülkü Nur Kırmızı², Muhammet Raşit Tural², Cemal Kocaaslan¹, Ebuzer Aydın¹

¹Department of Cardiovascular Surgery, Faculty of Medicine, Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, Turkey

²Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, Turkey

³Faculty of Medicine, Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, Turkey

Received: July 26, 2021 Accepted: October 18, 2021 Published online: November 12, 2021

ABSTRACT

Objectives: In this study, we aimed to assess whether higher preoperative levels of glycated hemoglobin (HbA1c) could predict primary arteriovenous fistula (AVF) failure and to investigate the effect of diabetes mellitus on primary arteriovenous failure.

Patients and methods: Between July 2018 and August 2019, a total of 127 newly created AVFs in 117 patients (67 males, 50 females; mean age: 62.4±12.2 years; range, 18 to 86 years) who underwent primary AVF operation in our cardiovascular surgery clinic were retrospectively analyzed. Medical data were obtained from the institutional database. Arteriovenous fistula failure was evaluated during follow-up.

Results: Primary AVF failure was seen in 24 (18.9%) patients. Patients with diabetes mellitus had a higher ratio of failure compared to those without (62.5% vs. 38.8%, respectively; p=0.035). After adjustment, diabetes mellitus was not found to be an independent risk factor for AVF failure (p>0.05). There was no significant correlation between HbA1c levels and fistula failure (p>0.05).

Conclusion: Our study results suggest that diabetes is associated with AVF failure, but it is not an independent risk factor for AVF failure. Higher HbA1c levels fail to predict AVF failure.

Keywords: Arteriovenous fistula, blood glucose, diabetes mellitus, glycated hemoglobin.

Diabetes mellitus (DM) is the leading etiology in chronic kidney disease (CKD), and it is commonly accompanied by vascular complications.^[1,2] Other than changes in vascular homeostasis and accompanying medical conditions, prolonged hyperglycemia, itself, also plays a role in the pathophysiology of the vascular damage in these patients.^[2] Glycated hemoglobin (HbA1c) is the preferred blood marker of glycemic control in patients with DM and the current guideline of Kidney Disease Outcomes Quality Initiative (KDOQI) recommends a target HbA1c of <7% for DM patients, irrespective of the presence of CKD.^[1]

Arteriovenous fistula (AVF) is the recommended vascular access type for hemodialysis according to the recent guideline of KDOQI.^[3] In addition to AVF having superior patency and lower re-intervention rates compared to other vascular access types, it has been found to be associated with lower rates of complication, infection, hospitalization, and depression and reduced costs and increased survival benefits.^[4-7] Nevertheless,

fistula failure is still a challenge. Identifying the factors affecting primary AVF failure is crucial to improve the implementation of optimal hemodialysis therapy. Since DM is the most commonly accompanying disease on CKD, assessment of the effect of DM-related parameters on AVF patency is of particular importance.

Considering that hyperglycemia is one of the reasons of vascular damage in patients with diabetes, we hypothesized that levels of HbA1c could affect AVF maturation. In the present study, we aimed to investigate whether higher preoperative levels of HbA1c could predict primary AVF failure and to

Corresponding author: Betül Nur Keser, MD. İstanbul Medeniyet Üniversitesi Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi Kalp ve Damar Cerrahisi Kliniği, 34722 Kadıköy, İstanbul, Türkiye.
Tel: +90 216 - 280 33 33 e-mail: keserbetulnur@gmail.com

Citation:

Keser BN, Kaya F, Sandal V, Kırmızı ÜN, Tural MR, Kocaaslan C, et al. Hemoglobin A1c levels do not predict primary arteriovenous fistula failure in hemodialysis patients. *Cardiovasc Surg Int* 2021;8(3):139-144.

examine the optimal cut-off value of HbA1c level to predict AVF failure.

PATIENTS AND METHODS

This single-center, retrospective study was conducted at Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Department of Cardiovascular Surgery between July 2018 and August 2019. Initially, a total of 199 primary AVF operations were screened. Exclusion criteria were as follows: age <18 years (n=8), undergoing arteriovenous graft operation and having incomplete data (n=15). In addition, six patients who died before the study was completed and 43 patients who were lost-to-follow-up were excluded. Finally, a total of 127 newly created AVFs in 117 patients (67 males, 50 females; mean age: 62.4±12.2 years; range, 18 to 86 years) were included in the study. A written informed consent was obtained from each patient. The study protocol was approved by the Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital Ethics Committee (No. 0034-2019). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Data collection

Data including demographic and clinical characteristics of the patients such as age, sex, height, weight and smoking habit; comorbidities (e.g., hypertension, DM, and peripheral artery disease); usage of antiplatelet or anticoagulant medications, history of undergoing hemodialysis through central venous catheter (CVC); and AVF failure were noted. Patients with DM or hypertension were identified as the ones who were under treatment with oral antidiabetic drugs or insulin, and antihypertensive drugs, respectively. Preoperative levels of red blood cells, HbA1c, blood glucose, white blood cells, platelet count, creatinine, and estimated glomerular filtration rate were documented. The tests were done up to two weeks prior to operations. All the values were measured by the hospital laboratory, and there was no considerable change in the measurement methods during the study.

Preoperative Doppler ultrasound mapping was routinely performed to each patient, and vascular diameters were noted. All operated patients had a vein diameter over 2.5 mm under tourniquet and an artery diameter over 2.0 mm. All operations were performed by a single surgeon and, thus, the surgical

approach to AVF creation was similar. The primary outcome of this study was primary AVF failure at six weeks. Primary AVF failure was defined as thrombosis or failure to mature at six weeks.^[8] Failure to mature was defined as insufficient flow to maintain dialysis or the inability to cannulate an AVF, if required.^[9]

Statistical analysis

Statistical analysis was performed using the IBM SPSS version 24.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were expressed in mean ± standard deviation (SD), median (min-max) or number and frequency, where applicable. The Kolmogorov-Smirnov test was applied to test normality. The Pearson chi-square, Mann-Whitney U, Kruskal-Wallis, and binary logistic regression tests were implemented, accordingly. Multiple logistic regression analyses were applied to evaluate independent risk factors for AVF failure. The variables included in the regression models were selected using the forward selection method. Multicollinearity diagnosis tests were performed for both multiple logistic regression models. The receiver operating characteristic (ROC) curve analysis was performed to identify the optimal cut-off value of HbA1c level to predict AVF failure. A *p* value of <0.05 was considered statistically significant.

RESULTS

The rate of DM and hypertension was 43.3% (n=55) and 76.4% (n=97), respectively. A total of 94 (74.0%) of the operations were distal radiocephalic AVF operations, while there were 23 (18.1%) proximal radiocephalic, four (3.1%) brachio basilic and six (4.7%) brachiocephalic AVF operations. Primary failure was seen in 24 operations (18.9%). Demographic and clinical characteristics of the patients with and without primary AVF failure are summarized in Table 1.

Diabetes mellitus was found to be associated with AVF failure. Patients with DM had a statistically significantly higher ratio of failure (15/55; 27.3%), compared to those without DM (9/72; 12.5%) (*p*=0.035). Nevertheless, after adjustment, neither DM nor other parameters were found to be independent risk factors for AVF failure (Table 2). In addition, there was no significant correlation

Table 1
Demographic and clinical characteristics of patients with and without primary AVF failure

Variables	Interventions with primary AVF failure (n=24)			Interventions without primary AVF failure (n=103)			p
	n	%	Mean±SD	n	%	Mean±SD	
Age (year)			63.9±9.4			62.0±12.8	0.490
Sex							
Female	11	45.8		39	37.9		0.472
Comorbidities							
Diabetes mellitus *	15	62.5		40	38.8		0.035
Hypertension	17	70.8		80	77.7		0.478
Peripheral arterial disease	4	16.7		12	11.7		0.505
Obesity	9	37.5		30	29.1		0.477
Hemoglobin (g/dL)			10.9±2.0			10.5±1.8	0.319
HbA1c (%)			6.0±0.7			6.3±1.5	0.406
Blood glucose (mg/dL)			130.9±46.6			120.8±52.0	0.394
Platelet count (10 ³ /μL) *			196.5±66.3			246.8±178.4	0.029
Body mass index (kg/m ²)			28.2±4.1			27.0±5.5	0.318
Smoking status							
Currently smoking	4	16.7		16	15.5		
Ex-smoker	10	41.7		33	32.0		
Never smoked	10	41.7		54	52.4		
History of CVC	14	58.3		44	42.7		0.123
History of hemodialysis	15	62.5		53	51.5		0.249
Usage of antithrombotic drugs	18	75.0		72	69.9		0.621

AVF: Arteriovenous fistula; SD: Standard deviation; HbA1c: Glycated hemoglobin; CVC: Central venous catheter; * p<0.05.

between HbA1c levels and primary AVF failure (p=0.406). The ROC curve analysis established no cut-off value of HbA1c level to predict primary AVF failure.

Patients with DM were older (p<0.001), had higher prevalence of hypertension (p=0.035), peripheral

artery disease (p=0.001), and antithrombotic drug use (p=0.018), had higher levels of blood glucose (p<0.001) and HbA1c (p<0.001), higher body mass index values (p=0.014) and lower creatinine levels (p=0.020).

In subgroup analysis containing only patients with DM (n=55), mean blood glucose level was

Table 2
Multivariate logistic regression for primary arteriovenous fistula failure

Covariates	Adjusted Odds Ratio	95% CI	p
Age	0.988	0.938-1.040	0.640
Diabetes mellitus	2.455	0.488-12.347	0.276
HbA1c (%)	0.782	0.403-1.518	0.467
Blood glucose (mg/dL)	0.999	0.987-1.012	0.933
Hypertension	0.730	0.191-2.789	0.645
Peripheral artery disease	0.926	0.144-5.963	0.935
Platelet count (10 ³ /μL)	0.995	0.987-1.003	0.245
Antiplatelet usage	1.025	0.327-3.212	0.967

HbA1c: Glycated hemoglobin; CI: Confidence interval.

Table 3
Selected characteristics of the patients with diabetes mellitus

Variables	Interventions with primary AVF failure (n=15)			Interventions without primary AVF failure (n=40)			<i>p</i>
	n	%	Mean±SD	n	%	Mean±SD	
Age (year)			67.0±7.7			67.8±10.4	0.783
Sex							
Female	7	46.7		35	87.5		0.912
Comorbidities							
Hypertension	12	80.0		35	87.5		0.482
Peripheral arterial disease	4	26.7		9	22.5		0.746
Obesity	6	40.0		14	35.0		0.731
Hemoglobin (g/dL)			10.7±1.9			10.5±1.8	0.735
HbA1c (%)			6.2±0.7			7.2±1.7	0.054
Blood glucose (mg/dL)			152.7±47.4			158.1±60.8	0.759
Antidiabetic drug type							0.452
Insulin	11	73.3		25	62.5		
Oral antidiabetic	4	26.7		15	37.5		
Platelet count (10 ³ /μL) *			185.5±66.5			242.9±72.4	0.016
Body mass index (kg/m ²)			29.2±3.7			28.4±5.3	0.584
History of CVC	10	66.7		16	40.0		0.051
History of hemodialysis	11	73.3		22	55.0		0.142
Usage of antithrombotic drugs	13	86.7		32	80.0		0.568

AVF: Arteriovenous fistula; SD: Standard deviation; HbA1c: Glycated hemoglobin; CVC: Central venous catheter; * *p*<0.05.

Table 4
Multivariate logistic regression for primary arteriovenous fistula failure in patients with diabetes mellitus

Covariates	Adjusted Odds Ratio	95% CI	<i>p</i>
HbA1c (%)	0.543	0.237-1.244	0.149
Platelet count (10 ³ /μL)	0.993	0.980-1.006	0.275

HbA1c: Glycated hemoglobin; CI: Confidence interval.

156.7±57.3 mg/dL and mean HbA1c value was 7.0±1.6%. Characteristics of the patients with DM are summarized in Table 3. No significant correlation was detected between blood glucose levels and HbA1c levels in patients with DM (*p*=0.433). The HbA1c level was not associated with AVF failure (*p*=0.054). Lower levels of platelet count were observed in patients with AVF failure (*p*=0.016). However, adjustment tests eliminated the statistical significance of the observations, and analysis revealed no independent risk factor for AVF failure in hemodialysis patients with DM (Table 4). No multicollinearity was detected in both regression models.

DISCUSSION

In the present study, the primary AVF failure was seen in 18.9% of the operations. Our study revealed that patients with DM had a statistically significantly higher ratio of primary AVF failure, but DM was not an independent risk factor for AVF failure. Higher levels of HbA1c failed to predict AVF failure.

A recent meta-analysis demonstrated a higher rate of AVF failure in patients with diabetes,^[10] which is consistent with our study. Other than hyperglycemia inducing vascular damage itself, metabolic changes accompanying DM such as endothelial damage and endothelial dysfunction impair venous remodeling

and may result in failure to mature.^[2,10] Besides, DM is associated with an increased extracellular matrix deposition, deregulated growth factors, and pro-thrombotic activity and it is a known risk factor for atherosclerosis, which all may promote AVF failure.^[11]

Our study demonstrated that preoperative levels of HbA1c failed to be a predictor of AVF failure. No consensus has been reached in the literature on whether HbA1c level has an impact on AVF failure. Some authors have advocated that HbA1c $\geq 7\%$ is associated with higher rates of AVF failure or lower patency rate,^[12,13] whereas a recent prospective study has shown that HbA1c level is not related to delayed maturity.^[14] Afsar and Elsurur^[12] explain their findings mainly based on the assumptions that greater HbA1c levels indicate presence of DM and that greater HbA1c levels suggest poor glycemic control. The authors also suggested that peripheral artery disease, which they found to be associated with the increased HbA1c levels, might affect AVF failure. Singh et al.^[14] observed that those with HbA1c $< 6.5\%$ had higher rates of AVF maturity at six weeks post-creation. Nevertheless, they demonstrated no significant relationship between HbA1c status and delayed maturity. Wu et al.^[13] reported a direct effect of hyperglycemia on endothelium, yet underlined their apprehension on whether baseline glycemic status could reflect the severity of underlying diabetes.

Hyperglycemia is known to create tendency to thrombosis via blood flow retardation and platelet aggregation,^[10] which may eventually cause AVF failure. Although recent guidelines recommend the same target level of HbA1c for patients with and without CKD, it is a matter of debate whether HbA1c level predicts blood glucose control accurately in CKD patients. It has been suggested by many authors that the correlation between HbA1c and blood glucose is impaired in CKD patients and that HbA1c may not be a reliable indicator of blood glucose control in these patients.^[15,16] Reduced red blood cell survival and common use of erythropoietin-stimulating agents increase the rate of young erythrocytes in these patients. These erythrocytes have less exposure time to glucose, which affects HbA1c levels. Several studies have indicated that the measured HbA1c levels of diabetic CKD patients are lower than indicated by their blood glucose levels, and thus HbA1c level misrepresents glycemic control.^[15,17] Although it is beyond of our scope to assess the predictive value of HbA1c level

on blood glucose level in CKD patients, our analysis revealed no significant correlation between blood glucose levels and HbA1c levels in hemodialysis patients with DM. Although hyperglycemia seems to be an important parameter affecting AVF failure, it may be misleading to assess HbA1c as an accurate predictor of blood glucose control in CKD patients. This may explain our finding that HbA1c level is not associated with AVF failure.

Vascular hyperglycemic memory is a relatively recent definition, describing the persistence of the effects of hyperglycemic stress, even though the blood glucose is normalized.^[2] This phenomenon makes the predictive value of the biochemical markers, which can only suggest recent blood glucose control, on vascular outcomes questionable, since recent blood glucose normalization does not rule out previous long-term hyperglycemia. Although the reliability of different markers remains being a matter of debate, it seems that any of these markers would be effective to predict AVF failure.

In our study, lower levels of platelet count were observed in patients with AVF failure. Although it is beyond doubt that thrombosis plays a role in the failure mechanism, an inverse association between platelet count and AVF failure is unexpected. Future studies should be made to analyze the effect of thrombosis-related parameters on AVF failure.

The single-center, retrospective design with a relatively small sample size with AVF failure are the main limitations of our study. Another limitation is that no subgroup analysis was able to be made considering AVF locations. The AVFs with different arteries and veins may have different characteristics which can affect AVF maturation and, thus, AVF failure. However, our study includes only autogenous AVFs, created by a single surgeon, eliminating the effect of surgical approach on fistula failure. Besides, we reviewed an adequate number of primary AVF operations, suggesting that there is no predictive value of preoperative HbA1c on primary AVF failure.

In conclusion, diabetes is associated with AVF failure irrespective of the patients' HbA1c levels. Although hyperglycemia seems to play a role in pathogenesis, there is a growing concern that HbA1c level may not be accurately indicating blood glucose control in CKD patients. In addition, considering that biochemical markers fail to present previous long-term hyperglycemia, predictive value of these markers on

vascular outcomes is limited. Based on these findings, the role of preoperative HbA1c is limited in predicting primary AVF failure.

Acknowledgements

We would like to thank Prof. Dr. Hasan Güçlü, from the Department of Biostatistics, Faculty of Medicine, Istanbul Medeniyet University for his valuable assistance in statistical analysis.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am J Kidney Dis* 2012;60:850-86.
2. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. *Eur Heart J* 2013;34:2436-43.
3. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. *Am J Kidney Dis* 2020;75(4 Suppl 2):S1-S164.
4. Hu H, Patel S, Hanisch JJ, Santana JM, Hashimoto T, Bai H, et al. Future research directions to improve fistula maturation and reduce access failure. *Semin Vasc Surg*. 2016;29:153-71.
5. Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, et al. Fistula first breakthrough initiative: Targeting catheter last in fistula first. *Semin Dial* 2012;25:303-10.
6. Konner K, Nonnast-Daniel B, Ritz E. The arteriovenous fistula. *J Am Soc Nephrol* 2003;14:1669-80.
7. Keser BN, Kirman UN, Kocaaslan C, Aydin E. The association between vascular access type and depressive symptoms in geriatric hemodialysis population. *Vascular* 2020;28:390-5.
8. Rooijens PP, Tordoir JH, Stijnen T, Burgmans JP, Smet de AA, Yo TI. Radiocephalic wrist arteriovenous fistula for hemodialysis: Meta-analysis indicates a high primary failure rate. *Eur J Vasc Endovasc Surg* 2004;28:583-9.
9. Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ; CIMINO study group. Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative. *Clin J Am Soc Nephrol* 2008;3:714-9.
10. Yan Y, Ye D, Yang L, Ye W, Zhan D, Zhang L, et al. A meta-analysis of the association between diabetic patients and AVF failure in dialysis. *Ren Fail* 2018;40:379-83.
11. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. *J Am Coll Cardiol* 1996;27:528-35.
12. Afsar B, Elsurur R. The primary arteriovenous fistula failure-a comparison between diabetic and non-diabetic patients: glycemic control matters. *Int Urol Nephrol* 2012;44:575-81.
13. Wu CC, Wen SC, Yang CW, Pu SY, Tsai KC, Chen JW. Baseline plasma glycemic profiles but not inflammatory biomarkers predict symptomatic restenosis after angioplasty of arteriovenous fistulas in patients with hemodialysis. *Atherosclerosis* 2010;209:598-600.
14. Singh P, Ariffin Z, Tajri H, Md Idris A, Suryati L, Sofida L. ROGA VF STUDY 2019 - Relationship of HbA1C (GLYCEMIC Control) on outcomes of AV FISTULAS: A prospective observational study. *Arch Surg Clin Res* 2019;3:53-55.
15. Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. *Nephrology (Carlton)* 2012;17:182-8.
16. Agarwal R, Light RP. Relationship between glycosylated hemoglobin and blood glucose during progression of chronic kidney disease. *Am J Nephrol* 2011;34:32-41.
17. Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycosylated albumin (GA). *J Med Invest* 2006;53:223-8.